Authors - Annals of the Rheumatic Diseases
BMJ is committed to ensuring that all good quality research is published. Our article transfer service helps authors find the best journal for their research while providing an easy and smooth publication process. If authors agree to transfer their manuscript, all versions, supplementary files and peer reviewer comments are automatically transferred; without …
Homepage | Annals of the Rheumatic Diseases
3 days ago · The homepage of Annals of the Rheumatic Diseases, a leading rheumatology journal published by BMJ and EULAR.
EULAR recommendations for the management of psoriatic arthritis …
Objective New modes of action and more data on the efficacy and safety of existing drugs in psoriatic arthritis (PsA) required an update of the EULAR 2019 recommendations for the pharmacological treatment of PsA. Methods Following EULAR standardised operating procedures, the process included a systematic literature review and a consensus meeting of 36 international experts in April 2023.
EULAR recommendations for the management of ANCA …
Background. The antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) include granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic GPA (EGPA).1–3 AAV represent a subgroup within the spectrum of primary systemic vasculitis defined by the Chapel Hill consensus conference nomenclature.4 In 2009, the EULAR developed its first recommendations ...
EULAR recommendations for the management of rheumatoid …
Objectives To provide an update of the EULAR rheumatoid arthritis (RA) management recommendations addressing the most recent developments in the field. Methods An international task force was formed and solicited three systematic literature research activities on safety and efficacy of disease-modifying antirheumatic drugs (DMARDs) and glucocorticoids (GCs). The new evidence was discussed in ...
Systemic lupus erythematosus - Annals of the Rheumatic Diseases
Objectives This study aims to evaluate the safety and efficacy of BCMA-CD19 compound chimeric antigen receptor T cells (cCAR) to dual reset the humoral and B cell immune system in patients with systemic lupus erythematosus (SLE) with lupus nephritis (LN). Methods This is a single-arm open-label multicentre phase 1 study of BCMA and CD19-directed cCAR in …
B-cell depletion in autoimmune diseases - Annals of the …
B cells have a pivotal function in the pathogenesis of autoimmune diseases, such as rheumatoid arthritis, multiple sclerosis and systemic lupus erythematosus. In autoimmune disease, B cells orchestrate antigen presentation, cytokine production and autoantibody production, the latter via their differentiation into antibody-secreting plasmablasts and …
EULAR recommendations for the management of …
The objective was to develop evidence-based recommendations for the management of antiphospholipid syndrome (APS) in adults. Based on evidence from a systematic literature review and expert opinion, overarching principles and recommendations were formulated and voted. High-risk antiphospholipid antibody (aPL) profile is associated with greater risk for thrombotic and obstetric APS. Risk ...
Efficacy and safety of sequential therapy with subcutaneous …
Objectives Disease activity control in patients with systemic lupus erythematosus (SLE) with corticosteroid and immunosuppressant withdrawal is a treatment goal. We evaluated whether this could be attained with sequential subcutaneous belimumab (BEL) and one cycle of rituximab (RTX). Methods In this phase 3, double-blind BLISS-BELIEVE trial (GSK Study 205646), patients with active SLE ...
Integrated safety analysis of filgotinib in patients with moderate-to ...
Objectives To update the long-term safety profile of filgotinib, a Janus kinase-1 preferential inhibitor, in patients with moderate-to-severe rheumatoid arthritis. Methods Data from seven trials were integrated ([NCT01888874][1], [NCT01894516][2], [NCT02889796][3], [NCT02873936][4], [NCT02886728][5], [NCT02065700][6] and [NCT03025308][7]). Patients received once-daily filgotinib 100 mg or 200 ...